31P-MRS and Huntington Disease (PRO-MH)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01359774|
Recruitment Status : Completed
First Posted : May 25, 2011
Last Update Posted : September 21, 2012
|Condition or disease||Intervention/treatment|
|Huntington Disease||Other: 31P-MR spectroscopy Other: 31P-RMN spectroscopy|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||31Phosphorus-Magnetic Resonance Spectroscopy and Huntington Disease|
|Study Start Date :||April 2011|
|Primary Completion Date :||April 2012|
|Study Completion Date :||April 2012|
Other: 31P-MR spectroscopy
Brain energy deficit is quantified using 31P-MR spectroscopy
Other: 31P-RMN spectroscopy
Brain energy deficit is quantified using 31P-RMN spectroscopy
- Brain energy deficit in Huntington patients [ Time Frame: one year ]
31P-MRS allows quantification of high-energy phosphate metabolites such as ATP and phosphocreatine.
Objective: to look at brain energy metabolism during rest and activation.
- Correlating a brain energy deficit with (i) biochemical parameters and (ii) clinical parameters in Huntington patients [ Time Frame: one year ]
Biochemical parameters include metabolites that we previously showed to be biomarkers in HD: branched chain amino acids and IGF1.
Clinical parameters include UHDRS and TFC.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01359774
|Hopital de la Pitié-Salpetrière|
|Paris, France, 75013|
|Principal Investigator:||Fanny Mochel, MD, PhD||INSERM UMR S975 Institut du Cerveau et de la Moelle, AP-HP Département de Génétique, Université Pierre et Marie Curie, Paris France|